Bayer AG PK Financials
| BAYRYDelisted Stock | USD 16.86 0.86 5.37% |
Bayer |
Understanding current and past Bayer AG Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bayer AG's financial statements are interrelated, with each one affecting the others. For example, an increase in Bayer AG's assets may result in an increase in income on the income statement.
The data published in Bayer AG's official financial statements usually reflect Bayer AG's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Bayer AG PK. For example, before you start analyzing numbers published by Bayer accountants, it's critical to develop an understanding of what Bayer AG's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Bayer AG's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bayer AG's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Bayer AG's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bayer AG PK. Please utilize our Beneish M Score to check the likelihood of Bayer AG's management manipulating its earnings.
Bayer AG Stock Summary
Bayer AG competes with Novartis, Sanofi ADR, AstraZeneca PLC, GlaxoSmithKline PLC, and Bristol Myers. Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany. Bayer Aktienges is traded on OTC Exchange in the United States.Specialization | Healthcare, Biotechnology |
| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US0727303028 |
| CUSIP | 072730302 |
| Location | Germany |
| Business Address | Kaiser-Wilhelm-Allee 1, Leverkusen, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.bayer.com |
| Phone | 49 214 30 1 |
| Currency | USD - US Dollar |
You should never invest in Bayer AG without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Bayer Pink Sheet, because this is throwing your money away. Analyzing the key information contained in Bayer AG's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Bayer AG Key Financial Ratios
Generally speaking, Bayer AG's financial ratios allow both analysts and investors to convert raw data from Bayer AG's financial statements into concise, actionable information that can be used to evaluate the performance of Bayer AG over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Bayer AG PK reports annually and quarterly.Bayer Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bayer AG's current stock value. Our valuation model uses many indicators to compare Bayer AG value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bayer AG competition to find correlations between indicators driving Bayer AG's intrinsic value. More Info.Bayer AG PK is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies reporting about 0.44 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Bayer AG PK is roughly 2.26 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bayer AG by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bayer AG's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bayer AG's earnings, one of the primary drivers of an investment's value.Bayer AG Market Pulse
| Quote | 16.86 |
| Change(%) | 5.37 |
| Change | 0.86 |
| Open | 16.0 |
| Low | 15.88 |
| High | 16.91 |
| Volume | 0 |
| Exchange | PINK |
About Bayer AG Financials
What exactly are Bayer AG Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Bayer AG's income statement, its balance sheet, and the statement of cash flows. Potential Bayer AG investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Bayer AG investors may use each financial statement separately, they are all related. The changes in Bayer AG's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bayer AG's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Bayer AG Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Bayer AG is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Bayer has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Bayer AG's financials are consistent with your investment objective using the following steps:- Review Bayer AG's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Bayer AG's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Bayer AG's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Bayer AG's stock is overvalued or undervalued.
Bayer AG April 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Bayer AG help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bayer AG PK. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bayer AG PK based on widely used predictive technical indicators. In general, we focus on analyzing Bayer Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bayer AG's daily price indicators and compare them against related drivers.
| Downside Deviation | 1.88 | |||
| Information Ratio | 0.1616 | |||
| Maximum Drawdown | 9.27 | |||
| Value At Risk | (3.65) | |||
| Potential Upside | 4.24 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Bayer Pink Sheet
If you are still planning to invest in Bayer AG PK check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bayer AG's history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |